| Abstract: |
Metastatic prostate cancer is characterized by recurrent genomic copy number alterations that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss as a cause of antiandrogen resistance in an in vivo small hairpin RNA (shRNA) screen of 730 genes deleted in prostate cancer. ATAC-seq and RNA-seq analyses showed that CHD1 loss resulted in global changes in open and closed chromatin with associated transcriptomic changes. Integrative analysis of this data, together with CRISPR-based functional screening, identified four transcription factors (NR3C1, POU3F2, NR2F1, and TBX2) that contribute to antiandrogen resistance, with associated activation of non-luminal lineage programs. Thus, CHD1 loss results in chromatin dysregulation, thereby establishing a state of transcriptional plasticity that enables the emergence of antiandrogen resistance through heterogeneous mechanisms. © 2020 Elsevier Inc. Performing an in vivo shRNA screen, Zhang et al. identify that CHD1 loss confers antiandrogen resistance. Low CHD1 levels correlate with shorter clinical responses to enzalutamide. CHD1 loss induces global chromatin changes, increasing expression of transcription factors that contribute to antiandrogen resistance. © 2020 Elsevier Inc. |
